Lonidamine: Efficacy and safety in clinical trials for thetreatment of solid tumors
Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Cognetti(Apple (Israel)), Paolo Carlini(National Cancer Institute), Alessandra Fabi(Agostino Gemelli University Polyclinic), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Paola Papaldo(Cancer Institute (WIA))
Cited by 168
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
|Journal of Clinical Oncology|2020|226